Business Standard

Tuesday, December 24, 2024 | 09:53 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

How future with lower Covid death rate seems like a worthy investment

Unfortunately, turning nasal vaccines into reality has a long way to go. The same is true for any newer approach to combatting Covid

Photo: Unsplash/Mufid Majnun
Premium

Photo: Unsplash/Mufid Majnun

Lisa Jarvis | Bloomberg Opinion
Last week, the Food and Drug Administration’s vaccine advisory committee paved the way for a simpler, flu-like plan for Covid. Everyone, whether they’ve been vaccinated before or not, will get a shot tailored to variants on the virus. And likely, people will get those shots once every fall.
 
The panel’s recommendation was unanimous, but came after lengthy discussion about the limitations of the strategy. Some worried that the omicron-specific shots seem to offer little improvement over the original vaccine, while others were concerned that an annual shot was too frequent for some — or not frequent enough for others, especially

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in